Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Abstract Members of the human epidermal growth factor receptor (HER) family play a significant role in bladder cancer progression and may underlie the development of chemotherapy resistance. Dacomitinib is an irreversible tyrosine kinase inhibitor with structural specificity for the catalytic domain...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Petros D. Grivas, Kathleen C. Day, Andreas Karatsinides, Alyssa Paul, Nazia Shakir, Iya Owainati, Monica Liebert, Lakshmi P. Kunju, Dafydd Thomas, Maha Hussain, Mark L. Day
Formatua: Artikulua
Hizkuntza:English
Argitaratua: BMC 2013-10-01
Saila:Molecular Medicine
Gaiak:
Dacomitinib
Bladder Cancer Xenografts
Non-obese Diabetic/severe Combined Immunodeficiency (NOD/SCID)
Epidermal Growth Factor Receptor (EGFR)
Lapatinib
Sarrera elektronikoa:https://doi.org/10.2119/molmed.2013.00108

Internet

https://doi.org/10.2119/molmed.2013.00108

Antzeko izenburuak